Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study

R. Greil, A. Tedeschi, C. Moreno, B. Anz, L. Larratt, M. Simkovic, D. Gill, JG. Gribben, IW. Flinn, Z. Wang, LWK. Cheung, AN. Nguyen, C. Zhou, L. Styles, F. Demirkan

. 2021 ; 100 (7) : 1733-1742. [pub] 20210520

Jazyk angličtina Země Německo

Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc21018401

E-zdroje NLK Online Plný text

ProQuest Central od 1997-03-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2000-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1997-03-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-03-01 do Před 1 rokem

Odkazy
PubMed 34018029
DOI 10.1007/s00277-021-04536-6
Knihovny.cz E-zdroje

Anti-CD20 antibody treatments, such as obinutuzumab, have been associated with infusion-related reactions (IRRs). In the phase 3 iLLUMINATE study of ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab in first-line chronic lymphocytic leukemia/small lymphocytic lymphoma, IRRs were substantially reduced with ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab. We prospectively analyzed inflammatory cytokines to evaluate the impact of ibrutinib on circulating cytokine levels following obinutuzumab infusion. In iLLUMINATE, ibrutinib or chlorambucil was given approximately 30-120 min before the first obinutuzumab infusion. Cytokines evaluated were IFNγ, IL-6, IL-8, IL-10, IL-18, MCP-1, MIP-1α, MIP-1β, and TNFα. Changes in peak cytokine levels from baseline (immediately before obinutuzumab) to post-obinutuzumab infusion were compared between arms and between patients with versus without IRRs using Wilcoxon rank sum test. Of 228 treated patients, 95 on ibrutinib-obinutuzumab (15 with IRRs, 80 without) and 88 on chlorambucil-obinutuzumab (45 with IRRs, 43 without) with cytokine data were included. Irrespective of IRR occurrence, median increase in cytokines was lower with ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab for all cytokines (P < 0.01) except MIP-1β. Across treatment arms, post-obinutuzumab median increase in all cytokines except MIP-1β was greater in patients with versus without IRRs (P < 0.001). IL-6 and IL-8 elevations were associated with IRRs in both treatment arms. Among patients with IRRs, those receiving ibrutinib-obinutuzumab had lower post-obinutuzumab increases in IL-6, IL-8, IL-10, and MCP-1 (P < 0.04) than patients receiving chlorambucil-obinutuzumab. For patients in the ibrutinib-treatment arm, we observed a reduction in both the rate of clinically apparent IRRs and the levels of IRR-related cytokines and chemokines. This observation supports an immunomodulatory mechanism of action for ibrutinib. Clinical Trial Registration: NCT02264574.

000      
00000naa a2200000 a 4500
001      
bmc21018401
003      
CZ-PrNML
005      
20240418101926.0
007      
ta
008      
210728s2021 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-021-04536-6 $2 doi
035    __
$a (PubMed)34018029
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Greil, Richard $u IIIrd Medical Department Paracelsus Medical University, Salzburg Cancer Research Institute-CCCIT, Cancer Cluster Salzburg, Salzburg, Austria. r.greil@salk.at
245    10
$a Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study / $c R. Greil, A. Tedeschi, C. Moreno, B. Anz, L. Larratt, M. Simkovic, D. Gill, JG. Gribben, IW. Flinn, Z. Wang, LWK. Cheung, AN. Nguyen, C. Zhou, L. Styles, F. Demirkan
520    9_
$a Anti-CD20 antibody treatments, such as obinutuzumab, have been associated with infusion-related reactions (IRRs). In the phase 3 iLLUMINATE study of ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab in first-line chronic lymphocytic leukemia/small lymphocytic lymphoma, IRRs were substantially reduced with ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab. We prospectively analyzed inflammatory cytokines to evaluate the impact of ibrutinib on circulating cytokine levels following obinutuzumab infusion. In iLLUMINATE, ibrutinib or chlorambucil was given approximately 30-120 min before the first obinutuzumab infusion. Cytokines evaluated were IFNγ, IL-6, IL-8, IL-10, IL-18, MCP-1, MIP-1α, MIP-1β, and TNFα. Changes in peak cytokine levels from baseline (immediately before obinutuzumab) to post-obinutuzumab infusion were compared between arms and between patients with versus without IRRs using Wilcoxon rank sum test. Of 228 treated patients, 95 on ibrutinib-obinutuzumab (15 with IRRs, 80 without) and 88 on chlorambucil-obinutuzumab (45 with IRRs, 43 without) with cytokine data were included. Irrespective of IRR occurrence, median increase in cytokines was lower with ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab for all cytokines (P < 0.01) except MIP-1β. Across treatment arms, post-obinutuzumab median increase in all cytokines except MIP-1β was greater in patients with versus without IRRs (P < 0.001). IL-6 and IL-8 elevations were associated with IRRs in both treatment arms. Among patients with IRRs, those receiving ibrutinib-obinutuzumab had lower post-obinutuzumab increases in IL-6, IL-8, IL-10, and MCP-1 (P < 0.04) than patients receiving chlorambucil-obinutuzumab. For patients in the ibrutinib-treatment arm, we observed a reduction in both the rate of clinically apparent IRRs and the levels of IRR-related cytokines and chemokines. This observation supports an immunomodulatory mechanism of action for ibrutinib. Clinical Trial Registration: NCT02264574.
650    _2
$a adenin $x aplikace a dávkování $x analogy a deriváty $7 D000225
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D061067
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a chlorambucil $x aplikace a dávkování $7 D002699
650    _2
$a cytokiny $x krev $7 D016207
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a intravenózní infuze $7 D007262
650    _2
$a chronická lymfatická leukemie $x krev $x farmakoterapie $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a piperidiny $x aplikace a dávkování $7 D010880
650    12
$a premedikace $7 D011292
650    _2
$a prospektivní studie $7 D011446
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Tedeschi, Alessandra $u Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
700    1_
$a Moreno, Carol $u Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
700    1_
$a Anz, Bertrand $u Department of Medical Oncology, Tennessee Oncology, Chattanooga, TN, USA
700    1_
$a Larratt, Loree $u Department of Clinical Hematology, University of Alberta Hospital, Edmonton, Alberta, Canada
700    1_
$a Simkovic, Martin $u Department of Internal Medicine - Hematology, University Hospital and Medical School Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Gill, Devinder $u Department of Clinical Hematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
700    1_
$a Gribben, John G $u Centre for Haemato-Oncology, Queen Mary University of London, Barts Cancer Institute, London, UK
700    1_
$a Flinn, Ian W $u Center for Blood Cancers, Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA
700    1_
$a Wang, Zhengyuan $u Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
700    1_
$a Cheung, Leo W K $u Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
700    1_
$a Nguyen, Aaron N $u Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
700    1_
$a Zhou, Cathy $u Biostatistics, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
700    1_
$a Styles, Lori $u Clinical Science, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
700    1_
$a Demirkan, Fatih, $d 1965- $u Department of Hematology, Dokuz Eylül University, Izmir, Turkey $7 xx0316387
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 100, č. 7 (2021), s. 1733-1742
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34018029 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20240418101920 $b ABA008
999    __
$a ok $b bmc $g 1689499 $s 1138845
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 100 $c 7 $d 1733-1742 $e 20210520 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace